These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 21518001

  • 1. Risk factors for post-transplant lymphoproliferative disease in patients with cystic fibrosis.
    Saueressig MG, Boussaud V, Amrein C, Guillemain R, Souilamas J, Souilamas R.
    Clin Transplant; 2011; 25(4):E430-6. PubMed ID: 21518001
    [Abstract] [Full Text] [Related]

  • 2. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
    Omar H, Hägglund H, Gustafsson-Jernberg A, LeBlanc K, Mattsson J, Remberger M, Ringdén O, Sparrelid E, Sundin M, Winiarski J, Yun Z, Ljungman P.
    Transpl Infect Dis; 2009 Oct; 11(5):393-9. PubMed ID: 19497070
    [Abstract] [Full Text] [Related]

  • 3. Acute cellular rejection and Epstein-Barr virus-related post-transplant lymphoproliferative disorder in a pediatric lung transplant with low viral load.
    Calabrese F, Loy M, Lunardi F, Marino D, Aversa SM, Rea F.
    Transpl Infect Dis; 2010 Aug 01; 12(4):342-6. PubMed ID: 20030794
    [Abstract] [Full Text] [Related]

  • 4. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S, Renner C, Hammer M, Abdul-Khaliq H, Lehmkuhl HB, Berger F, Hetzer R, Reinke P.
    J Heart Lung Transplant; 2008 Jan 01; 27(1):100-5. PubMed ID: 18187094
    [Abstract] [Full Text] [Related]

  • 5. Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients.
    Lee TC, Savoldo B, Barshes NR, Rooney CM, Heslop HE, Gee AP, Caldwell Y, Scott JD, Goss JA.
    Clin Transplant; 2006 Jan 01; 20(3):389-93. PubMed ID: 16824159
    [Abstract] [Full Text] [Related]

  • 6. Increased risk of PTLD in lung transplant recipients with cystic fibrosis.
    Lowery EM, Adams W, Grim SA, Clark NM, Edwards L, Layden JE.
    J Cyst Fibros; 2017 Nov 01; 16(6):727-734. PubMed ID: 28456611
    [Abstract] [Full Text] [Related]

  • 7. Post-transplantation lymphoproliferative disease: Epstein-Barr virus DNA levels, HLA-A3, and survival.
    Wheless SA, Gulley ML, Raab-Traub N, McNeillie P, Neuringer IP, Ford HJ, Aris RM.
    Am J Respir Crit Care Med; 2008 Nov 15; 178(10):1060-5. PubMed ID: 18755927
    [Abstract] [Full Text] [Related]

  • 8. Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients.
    Manlhiot C, Pollock-Barziv SM, Holmes C, Weitzman S, Allen U, Clarizia NA, Ngan BY, McCrindle BW, Dipchand AI.
    J Heart Lung Transplant; 2010 Jun 15; 29(6):648-57. PubMed ID: 20304682
    [Abstract] [Full Text] [Related]

  • 9. Determining virological, serological and immunological parameters of EBV infection in the development of PTLD.
    Davis JE, Sherritt MA, Bharadwaj M, Morrison LE, Elliott SL, Kear LM, Maddicks-Law J, Kotsimbos T, Gill D, Malouf M, Falk MC, Khanna R, Moss DJ.
    Int Immunol; 2004 Jul 15; 16(7):983-9. PubMed ID: 15159377
    [Abstract] [Full Text] [Related]

  • 10. Quantitative Epstein-Barr virus (EBV) serology in lung transplant recipients with primary EBV infection and/or post-transplant lymphoproliferative disease.
    Verschuuren E, van der Bij W, de Boer W, Timens W, Middeldorp J, The TH.
    J Med Virol; 2003 Feb 15; 69(2):258-66. PubMed ID: 12683416
    [Abstract] [Full Text] [Related]

  • 11. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation.
    Sundin M, Le Blanc K, Ringdén O, Barkholt L, Omazic B, Lergin C, Levitsky V, Remberger M.
    Haematologica; 2006 Aug 15; 91(8):1059-67. PubMed ID: 16885046
    [Abstract] [Full Text] [Related]

  • 12. Epstein-Barr virus-DNA load monitoring late after lung transplantation: a surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression.
    Bakker NA, Verschuuren EA, Erasmus ME, Hepkema BG, Veeger NJ, Kallenberg CG, van der Bij W.
    Transplantation; 2007 Feb 27; 83(4):433-8. PubMed ID: 17318076
    [Abstract] [Full Text] [Related]

  • 13. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment.
    Muti G, Cantoni S, Oreste P, Klersy C, Gini G, Rossi V, D'Avanzo G, Comoli P, Baldanti F, Montillo M, Nosari A, Morra E, Cooperative Study Group on PTLDs.
    Haematologica; 2002 Jan 27; 87(1):67-77. PubMed ID: 11801467
    [Abstract] [Full Text] [Related]

  • 14. [Diffuse lymphoproliferative disease after renal transplantation and its relation with Epstein-Barr virus. Experience at one center].
    Franco A, Jiménez L, Aranda I, Alvarez L, González M, Rocamora N, Olivares J.
    Nefrologia; 2002 Jan 27; 22(5):463-9. PubMed ID: 12497748
    [Abstract] [Full Text] [Related]

  • 15. Incidence and outcome of primary Epstein-Barr virus infection and lymphoproliferative disease in pediatric heart transplant recipients.
    Zangwill SD, Hsu DT, Kichuk MR, Garvin JH, Stolar CJ, Haddad J, Stylianos S, Michler RE, Chadburn A, Knowles DM, Addonizio LJ.
    J Heart Lung Transplant; 1998 Dec 27; 17(12):1161-6. PubMed ID: 9883755
    [Abstract] [Full Text] [Related]

  • 16. Screening for PTLD in lung and heart-lung transplant recipients by measuring EBV DNA load in bronchoalveolar lavage fluid using real time PCR.
    Michelson P, Watkins B, Webber SA, Wadowsky R, Michaels MG.
    Pediatr Transplant; 2008 Jun 27; 12(4):464-8. PubMed ID: 18466434
    [Abstract] [Full Text] [Related]

  • 17. Post-transplant lymphoproliferative disease in lung transplantation: A nested case-control study.
    Leyssens A, Dierickx D, Verbeken EK, Tousseyn T, Verleden SE, Vanaudenaerde BM, Dupont LJ, Yserbyt J, Verleden GM, Van Raemdonck DE, Vos R.
    Clin Transplant; 2017 Jul 27; 31(7):. PubMed ID: 28383790
    [Abstract] [Full Text] [Related]

  • 18. Epstein-Barr virus seronegativity is a risk factor for late-onset posttransplant lymphoroliferative disorder in adult renal allograft recipients.
    Shahinian VB, Muirhead N, Jevnikar AM, Leckie SH, Khakhar AK, Luke PP, Rizkalla KS, Hollomby DJ, House AA.
    Transplantation; 2003 Mar 27; 75(6):851-6. PubMed ID: 12660514
    [Abstract] [Full Text] [Related]

  • 19. Associations of serum EBV DNA and gammopathy with post-transplant lymphoproliferative disease.
    Rosselet A, Vu DH, Meylan P, Chaubert AS, Schapira M, Pascual M, Aubert V, Tissot JD, Duchosal MA.
    Clin Transplant; 2009 Mar 27; 23(1):74-82. PubMed ID: 19200218
    [Abstract] [Full Text] [Related]

  • 20. Epstein Barr viral load monitoring by quantitative PCR in renal transplant patients.
    Merlino C, Cavallo R, Bergallo M, Giacchino F, Bollero C, Negro Ponzi A, Cavallo G.
    New Microbiol; 2003 Apr 27; 26(2):141-9. PubMed ID: 12737195
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.